Recently Published

• The author identifies four early-stage medical breakthroughs currently in clinical trials that could potentially treat major killers like cancer, heart disease, and neurodegenerative diseases. • While acknowledging that many promising medical ideas fail during development, these specific advances are being monitored with cautious optimism by leading research institutions.

• The author challenges the public health establishment's claim that universal vaccination is the essential tool for preventing epidemics like Covid-19, polio, and measles. • The piece argues that while medical science is effective at a micro level, a macro-level analysis of epidemic curves is necessary to understand disease trajectories.

• Former leaders from the FDA, CDC, and NIH convened at the BIO International Convention to discuss the dismantling of the Department of Health and Human Services under the Trump administration. • The panel focused on the collapse of existing US public health structures and the urgent need to rebuild a more effective system.

• The FDA has launched a new initiative aimed at resetting the drug review process to accelerate the development of new medications. • A primary goal of the program is to boost the number of domestic clinical trials, reducing reliance on overseas data and speeding up patient access to therapies.

• PwC reports that health services M&A activity remains active in 2026, with overall deal value increasing compared to the first half of 2025. • Despite higher values, deal volume is slowing as buyers become more selective due to reimbursement pressures and policy uncertainty.

• The US Administration is restructuring the systems supporting PEPFAR and global health security, shifting its engagement strategy toward regulatory influence over long-term public health partnerships. • Concerns are rising that increased political oversight and the deconstruction of international collaborations may undermine the NIH's scientific infrastructure and its history of HIV research and vaccine development.

• The FDA has accepted Roche's application to use the combination of Lunsumio and Polivy for patient treatment. • This regulatory milestone is part of Roche's effort to expand the indications and clinical utility of these existing in-market products.

• The ICH has introduced a new standardized framework for clinical trial protocols consisting of a harmonized guideline, a protocol template, and a technical specification for electronic exchange. • These documents apply to all phases and therapeutic areas of interventional clinical trials, including pharmaceuticals, biologics, vaccines, and cell or gene therapy products.

• The article alleges a cover-up regarding the origins of SARS-CoV-2, specifically highlighting the role of the DEFUSE project. • This project involved scientists from the U.S., foreign entities, and the Wuhan Institute of Virology who proposed modifying spike proteins of coronaviruses to model disease spread among U.S. Pacific forces.

• U.S. Health Secretary Robert F. Kennedy Jr. announced over $700 million in new funding opportunities on Wednesday to address mental illness, addiction, and homelessness. • The financial package includes $238.6 million for the 988 Suicide and Crisis Lifeline and $223.1 million for Certified Community Behavioral Health Clinics.

• Pfizer expanded its obesity pipeline through a $150 million deal for YaoPharma’s oral GLP-1 agonist and a separate $150 million investment in GLP-1 and amylin drug candidates. • Sanofi acquired Blueprint Medicines for $9.5 billion to secure oncology and rare disease assets, including the approved drug Ayvakit.